PMID- 36176390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221001
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in 
      chronic myeloid leukemia: Not only a dasatinib-related adverse event.
PG  - 1012268
LID - 10.3389/fonc.2022.1012268 [doi]
LID - 1012268
AB  - The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion 
      (PE) is a frequent AE attributable to dasatinib treatment, while it is only 
      rarely associated with nilotinib. The pathogenetic mechanism leading to PE during 
      nilotinib therapy is still unknown and its management has not yet been defined. 
      To the best of our knowledge, only a limited number of similar case reports have 
      already been reported in the literature so far. Here, we describe the case of a 
      41-year-old CML patient who developed PE during first-line nilotinib, 
      successfully treated with steroids and nilotinib permanent discontinuation. We 
      highlight the differences among our patient and the others, proposing therapeutic 
      strategies to solve this rare but still possible AE, of which physicians should 
      be aware.
CI  - Copyright (c) 2022 Pasquale, Bucelli, Bellani, Zappa, Iurlo and Cattaneo.
FAU - Pasquale, Raffaella
AU  - Pasquale R
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Bucelli, Cristina
AU  - Bucelli C
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Bellani, Valentina
AU  - Bellani V
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
FAU - Zappa, Manuela
AU  - Zappa M
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Iurlo, Alessandra
AU  - Iurlo A
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Cattaneo, Daniele
AU  - Cattaneo D
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
LA  - eng
PT  - Case Reports
DEP - 20220913
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9513037
OTO - NOTNLM
OT  - adverse event
OT  - chronic myeloid leukemia
OT  - nilotinib
OT  - pleural effusion
OT  - tyrosine-kinase inhibitor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/01 06:00
MHDA- 2022/10/01 06:01
PMCR- 2022/01/01
CRDT- 2022/09/30 02:27
PHST- 2022/08/05 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/09/30 02:27 [entrez]
PHST- 2022/10/01 06:00 [pubmed]
PHST- 2022/10/01 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.1012268 [doi]
PST - epublish
SO  - Front Oncol. 2022 Sep 13;12:1012268. doi: 10.3389/fonc.2022.1012268. eCollection 
      2022.